Kebriaei Partow, Poon Michelle Limei
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA,
Curr Hematol Malig Rep. 2015 Jun;10(2):76-85. doi: 10.1007/s11899-015-0251-8.
The prognosis of acute lymphoblastic leukemia (ALL) in adults remains poor, and novel treatment options are needed to improve outcomes. Immunotherapeutic strategies have been a recent focus in this area, targeting specific surface antigens on the ALL blast cells. Our review concentrates on four major class of antibody therapies, namely, (1) naked and unconjugated antibodies, (2) immunoconjugates and immunotoxins, (3) bi-specific T cell engaging (BiTE) therapy, and (4) chimeric antigen receptor (CAR) expressing T cells. We review preclinical and clinical data, and update on the latest advances in this exciting field, and suggest how these therapies can be incorporated into the treatment algorithm for ALL.
成人急性淋巴细胞白血病（ALL）的预后仍然很差，需要新的治疗方案来改善治疗结果。免疫治疗策略是该领域最近的研究重点，其针对ALL原始细胞上的特定表面抗原。我们的综述集中在四类主要的抗体疗法，即：（1）裸抗体和未偶联抗体；（2）免疫偶联物和免疫毒素；（3）双特异性T细胞衔接（BiTE）疗法；（4）表达嵌合抗原受体（CAR）的T细胞。我们综述了临床前和临床数据，介绍了这一令人兴奋的领域的最新进展，并提出了如何将这些疗法纳入ALL的治疗方案中。
